Sugi Predict

Sugi Predict / Compounds / SCHEMBL721833

SCHEMBL721833

SCHEMBL721833

Cc1ccc(S(=O)(=O)n2cc(I)c3cc(Br)cnc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.51
▸ ENPP3 O14638 1/20 0.42
▸ ENPP1 P22413 1/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALDH3A1 P30838 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ PTPN11 Q06124 1/20 0.41
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GAA P10253 1/20 0.37
▸ RAPGEF4 Q8WZA2 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ UBE2N P61088 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ PKM P14618 1/20 0.36
▸ MAPT P10636 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19250316 0.88 BRD4 (0.54) BRD4L3MBTL1POLBALDH3A1HTT
SCHEMBL15882765 0.87 ENPP3 (0.44) BRD4ENPP3ENPP1L3MBTL1POLB
SCHEMBL1043519 0.87 BRD4 (0.58) BRD4ENPP3ENPP1MEN1KMT2A
SCHEMBL15155315 0.85 ENPP3 (0.42) BRD4ENPP3ENPP1L3MBTL1POLB
SCHEMBL20846089 0.85 BRD4 (0.51) BRD4L3MBTL1POLBALDH3A1HTT
SCHEMBL12066672 0.85 BRD4 (0.51) BRD4L3MBTL1POLBALDH3A1HTT
SCHEMBL16186613 0.85 ENPP3 (0.42) BRD4ENPP3ENPP1L3MBTL1POLB
SCHEMBL18995268 0.85 BRD4 (0.51) BRD4L3MBTL1POLBALDH3A1HTT
SCHEMBL31150811 0.85 BRD4 (0.51) BRD4L3MBTL1POLBALDH3A1HTT
SCHEMBL20502438 0.84 PDE4A (0.44) BRD4ENPP3ENPP1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116143779-B Compound of hematopoietic progenitor cell kinase 1 inhibitor, preparation method and application thereof 中国药科大学 2025-06-13 — — CN disclosed
CN-114685490-B Pyrrolopyridine compound and application thereof 南京再明医药有限公司 2025-03-28 — — CN disclosed
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES INC 2025-03-27 — — US disclosed
CN-114685489-B Polysubstituted nitrogen-containing heterocyclic compound and application thereof 南京再明医药有限公司 2025-03-07 — — CN disclosed
EP-4340839-B1 NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS CENTRE NAT RECH SCIENT (FR) 2025-02-12 — — EP disclosed
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 — — US disclosed
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 — — US disclosed
US-12157741-B2 Macrocyclic inhibitors of DYRK1A DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-12-03 — — US disclosed
EP-4444721-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 — — EP disclosed
US-20240293400-A1 NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-09-05 — — US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 — — US disclosed
WO-2007106236-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-09-20 — — WO disclosed
EP-1781654-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2007-05-09 — — EP disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20060030583-A1 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2006-02-09 — — US disclosed
WO-2006015123-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2006-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR BRD4 2456/4885ENPP3 546/4885ENPP1 970/4885
US-20240293400-A1 NOVEL AZAINDOLE DERIVATIVES AS ANTIVIRAL AGENTS AXL, ZC3HAV1, MERTK BRD4 602/4885ENPP3 582/4885ENPP1 647/4885
US-20250099442-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS DYRK2, DYRK1A, DYRK1B BRD4 2431/4885ENPP3 2054/4885ENPP1 1431/4885
US-20060030583-A1 Pyrrolo-pyridine kinase modulators MAP3K20, MAP4K2, MAP3K19 BRD4 418/4885ENPP3 815/4885ENPP1 714/4885
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH BRD4 4291/4885ENPP3 1096/4885ENPP1 1738/4885
US-12157741-B2 Macrocyclic inhibitors of DYRK1A RET, DYRK1A, DYRK1B BRD4 1146/4885ENPP3 1700/4885ENPP1 1607/4885
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine MAP3K20, MAP4K2, MAP3K6 BRD4 367/4885ENPP3 594/4885ENPP1 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.